Advancements in Diagnostic and Preventive Pharmacogenomics
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 1541
Special Issue Editor
Special Issue Information
Dear Colleagues,
Advancements in diagnostic and preventive pharmacogenomics are revolutionizing the landscape of personalized medicine by leveraging novel genome profiling technologies. These innovations enable the precise detection of individuals’ genetic backgrounds, which are pivotal in understanding their responses to various drugs. High-throughput sequencing, including Next-Generation Sequencing (NGS) and long-read sequencing technologies, as well as comprehensive array-based targeted sequencing, facilitate comprehensive genetic analyses, uncovering gene–drug and gene–gene–drug interactions with unprecedented accuracy. By integrating these technologies into clinical practice, healthcare providers can tailor treatments to the genetic profiles of patients, thereby enhancing therapeutic efficacy and minimizing adverse drug reactions (ADRs). Such precision medicine approaches are particularly beneficial in complex cases where multiple genetic factors influence drug metabolism and response, offering a more holistic view of patient care.
The shift from point-of-care to pre-emptive genotyping represents a paradigm change in pharmacogenomics, with significant implications for preventive healthcare. Such genome screening approaches enable the anticipation and avoidance of potential ADRs. This proactive strategy not only enhances patient safety but also optimizes therapeutic outcomes by selecting the most appropriate drugs based on patients’ genetic predisposition. Moreover, the integration of pharmacogenomic data into electronic health records ensures that genetic information is readily accessible, facilitating informed decision-making by clinicians. As a result, pre-emptive genotyping has the potential to transform pharmacogenomics from a reactive to a preventive discipline, ultimately enhancing the quality and efficiency of healthcare.
Because of this, the correct and accurate detection of pharmacogenes’ star alleles can be considered the first step into the future of pharmacogenomics. The aim of this Special Issue is to compile and present new reports and studies addressing advancements in the genetic profiling of individuals, novel discoveries, and multi-omics technologies for the genetic analysis of drug-related genes. The results will enhance treatment outcomes, especially for those seeking drug stratification in clinical practice. Investigators working in this fascinating area are welcome to submit original research, review articles, case reports, and other relevant manuscripts to our Special Issue.
This Special Issue is supervised by Dr. Alireza Tafazoli, assisted by our Topical Advisory Panel Member Dr. Pantea Kiani (Department of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University).
Dr. Alireza Tafazoli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- genome profiling
- pharmacogenetic analysis
- diagnostic pharmacogenomics
- pre-emptive pharmacogenomics
- advanced genotyping technologies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
